Printer Friendly

Hard to Treat Diseases' (HTDS) MMR Vaccine Passed the Chinese SFDA's 'First Drug Evaluation'.

SHENZHEN, China, November 17 /PRNewswire/ -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) and its China subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and Rubella Combined Vaccine Live) had obtained a "pass" on its First Drug Evaluation.

On November 2, 2009, State Food and Drug Administration held a Drug Evaluation Conference to determine, whether HTDS' MMR vaccine meets the requirements for release onto the Chinese pharmaceutical market. HTDS' experts and representatives from the manufacturer (Serum Institute of India Ltd.) presented the MMR attenuated vaccine to the SFDA's expert panel. The HTDS' MMR vaccine received a "pass" on its First Drug Evaluation.

Based on the research and clinical trial results presented, the panel concurred that the Mellow Hope's MMR vaccine had a good safety profile, therefore, the vaccine will undergo further inquiry for the final SFDA approval. The First Drug Evaluation panel will submit the results for final approval. This approval will secure HTDS the production license for MMR vaccine.

Thrilled by the results, HTDS' CEO Terry Yuan said "We got the first "Pass" through this conference and this gives us much confidence to get the final approval. Now we are actively preparing for the clinical trial protocol designed exactly as per Chinese actual conditions. Taking the booster immunization into account, it is estimated that the market size in China will be 60 million doses per year."

Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europe and Mainland China. HTDS is a parent company with operations in East European Serbia based pharmaceutical company Slavica Bio Chem Co. and in China Mellow Hope Inc.

In other company news, the issuer also brings attention to certain news which was released by its partner Zhejiang Tianyuan Bio-Pharmaceutical Co, thus by default (Novaris becoming the new partner after the merger) where amongst other things Zhejiang Tianyuan Bio-Pharmaceutical Co disclosed a huge H1N1 sale to Chile. HTDS can confirm (and will provide updates shortly) that it has a role in that transaction with substantial gains to HTDS.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at http://www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

For further information: For any investor relations matters, please contact http://www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, http://www.minamargroup.net (IR); For (M&A) and Corporate Matters, http://www.minamargroup.com (HTDS) Jeffrey Allen, +1(647)-426-1640

Jeffrey Allen, +1(647)-426-1640
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Nov 17, 2009
Words:731
Previous Article:MasterCard Takes Payments Technology into the Future with the Launch of M/Chip(TM) Advance.
Next Article:Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters